TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA expanded approval of insulin icodec, sold as Awiqli, as the first once-weekly insulin indicated for children ages 10 and older with type 2 diabetes. Separately, a U.S. judge denied Novo Nordisk’s request to temporarily block Eli Lilly advertisements, and U.S. fertility data showed the rate fell to a record low in 2025.
The FDA has expanded approval of insulin icodec, sold as Awiqli, making it the first once-weekly insulin indicated for type 2 diabetes in children ages 10 and older, according to an October 27 endocrinology news roundup. The roundup also reported that a U.S. judge rejected Novo Nordisk’s request to temporarily stop Eli Lilly from running ads asserting that its weight-loss and diabetes drugs are more powerful, while U.S. fertility fell to a record low in 2025.
The FDA’s decision adds children ages 10 and older with type 2 diabetes to the indicated use for insulin icodec. The report described it as the first weekly insulin indicated for this group. It did not provide details about the FDA’s review, the evidence supporting the pediatric indication, prescribing conditions or when the expanded use will be available.
In a separate legal dispute, a U.S. judge denied Novo Nordisk’s request to temporarily block Eli Lilly advertisements that claim Lilly’s weight-loss and diabetes drugs are more powerful. The report did not specify which products or advertisements were at issue, quote the ads, or describe the judge’s reasoning. The denial concerns a request for temporary relief; the brief account does not establish the outcome of any broader dispute.
The roundup also cited CDC data showing a 1% decline in the U.S. fertility rate in 2025, to 53.2 births per 1,000 females ages 15 to 44. It characterized the rate as a record low. The report offered no further breakdown by age, state or other demographic group.
Weekly Insulin and Broader Health Stakes
The expanded indication gives clinicians and families another insulin schedule to consider for children with type 2 diabetes. A once-weekly regimen differs from daily insulin dosing, but the brief report does not establish whether it will improve adherence, outcomes or quality of life, or which patients may be appropriate candidates. Those questions depend on clinical evidence and individual care decisions.
The advertising ruling matters to the competing drugmakers and to readers trying to assess claims about medicines used for weight loss and diabetes. A judge’s refusal to impose a temporary block is not, by itself, a finding that every advertising claim is accurate or that the underlying dispute is resolved. The fertility figures, meanwhile, quantify a national demographic measure, but the supplied report does not identify why the rate declined or what the change means for particular communities.
Products Worth Considering
Hyperice Normatec Elite Wireless Compression Boots Recovery – Standard Size
Oura Ring 4 Smart Ring – Silver – Size 8
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Navy
As an affiliate, we earn on qualifying purchases.
Three Developments in One Roundup
The items appeared together in an endocrinology news roundup published October 27, 2026, rather than as one connected event. The legal item was attributed to Reuters via AOL; the pediatric insulin approval was reported in the roundup; and the fertility figures were attributed to CDC data. Each concerns a different area of health policy or practice.
The roundup also noted related research and industry developments: a cross-sectional study found endocrinologists were more likely to prescribe SGLT2 inhibitors and GLP-1 receptor agonists after American Diabetes Association guideline updates. A retrospective cohort study suggested GLP-1 use among Medicare beneficiaries with type 2 diabetes rose more than 16-fold from 2010 to 2022, with limited differences by cancer history. These findings are reported as study results, not proof that the guideline changes caused prescribing shifts or that the same trends apply to all patients.
“A U.S. judge rejected Novo Nordisk’s request to temporarily block Eli Lilly from running advertisements claiming its weight-loss and diabetes drugs are more powerful.”
— MedPage Today, citing Reuters via AOL
Details Still Missing From Reports
The supplied coverage does not include the FDA’s full decision, clinical-trial findings, safety information, labeling details or guidance on use of weekly insulin in children. It is also unclear when the expanded indication will reach patients and how clinicians may use it alongside existing treatments.
For the advertising dispute, the judge’s rationale, the precise wording and placement of the ads, and any next court dates are not provided. The report does not say whether Novo Nordisk plans another filing or appeal. For fertility, the cited number gives the national rate and its annual change, but not the causes of the decline or geographic and demographic patterns. The roundup’s brief summaries do not answer those questions.
Regulatory and Court Follow-Up
Further FDA materials and updated product information should clarify the terms of Awiqli’s expanded pediatric indication, including the supporting evidence and practical prescribing details. Families and clinicians will need to rely on the official labeling and qualified medical professionals when considering treatment; the roundup alone is not clinical guidance.
In the advertising case, the next meaningful developments would be any fuller court ruling, further filings or changes to the ads. The source does not provide a schedule. Additional CDC releases or analysis may offer more detail on the 2025 fertility figures, but no such follow-up was specified in the report.
Key Questions
What did the FDA approve for children with type 2 diabetes?
The FDA expanded approval of insulin icodec, sold as Awiqli, to include children ages 10 and older with type 2 diabetes. The report describes it as the first once-weekly insulin indicated for this group.
Did the judge rule that Eli Lilly’s advertising claims are true?
The report says the judge denied Novo Nordisk’s request for a temporary block. It does not say that the judge ruled on the truth of the advertisements or resolved the wider dispute.
How much did the U.S. fertility rate change in 2025?
It fell 1% to 53.2 births per 1,000 females ages 15 to 44, a rate the report described as a record low, citing CDC data.
When will the weekly insulin be available for eligible children?
The supplied report does not state when the expanded indication will be available or provide details about labeling and prescribing. Those specifics would need to be confirmed through FDA and product information.
Source: rss
